Trillium Therapeutics Inc. (TRIL) Reaches $1.25 52-Week Low; 1 Analysts Bullish Piedmont Office Realty Trust, Inc. (PDM)

Among 3 analysts covering Piedmont Office Realty (NYSE:PDM), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Piedmont Office Realty had 3 analyst reports since November 30, 2018 according to SRatingsIntel. The stock of Piedmont Office Realty Trust, Inc. (NYSE:PDM) has “Hold” rating given on Thursday, February 7 by Stifel Nicolaus. The rating was upgraded by SunTrust on Friday, November 30 to “Buy”. The stock has “Neutral” rating by Robert W. Baird on Wednesday, January 9. See Piedmont Office Realty Trust, Inc. (NYSE:PDM) latest ratings:

07/02/2019 Broker: Stifel Nicolaus Old Rating: Sell New Rating: Hold Old Target: $16 New Target: $20 Upgrade
09/01/2019 Broker: Robert W. Baird Old Rating: Outperform New Rating: Neutral Downgrade
30/11/2018 Broker: SunTrust Old Rating: Hold New Rating: Buy Upgrade

The stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) hit a new 52-week low and has $1.14 target or 9.00% below today’s $1.25 share price. The 9 months bearish chart indicates high risk for the $18.04 million company. The 1-year low was reported on Feb, 11 by Barchart.com. If the $1.14 price target is reached, the company will be worth $1.62 million less. The stock increased 2.46% or $0.03 during the last trading session, reaching $1.25. About 154,657 shares traded. Trillium Therapeutics Inc. (NASDAQ:TRIL) has declined 80.19% since February 11, 2018 and is downtrending. It has underperformed by 80.19% the S&P500. Some Historical TRIL News: 17/04/2018 – TRILLIUM ASSET MANAGEMENT URGES FACEBOOK SHAEHOLDERS TO VOTE IN FAVOR OF PROPOSAL REGARDING RISK OVERSIGHT COMMITTEE – SEC FILING; 14/03/2018 – S&PGR Asgns Rating To Trillium CC Trust II Notes Series 2018-1; 06/03/2018 – Moody’s Assigns Provisional Ratings To Trillium Credit Card Trust Ii 2018-1 Abs; 10/04/2018 – TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS; 06/03/2018 GUIDANCE: BANK OF NOVA SCOTIA $400M TRILLIUM CREDIT CARD ABS; 23/04/2018 – TRILLIUM: FB HOLDERS TO VOTE FOR RISK OVERSIGHT BOARD COMITTEE; 26/03/2018 – Trillium Dental Announces New Brand Identity; 11/05/2018 – TRILLIUM – AS OF MARCH 31, 2018, HAD CASH & CASH EQUIVALENTS & MARKETABLE SECURITIES, & WORKING CAPITAL OF $73.9 MLN AND $61.7 MLN, RESPECTIVELY; 13/03/2018 – Trillium Therapeutics Granted Orphan Drug Status by FDA; 18/04/2018 – Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting

Analysts await Trillium Therapeutics Inc. (NASDAQ:TRIL) to report earnings on March, 8. They expect $-0.66 earnings per share, up 8.33% or $0.06 from last year’s $-0.72 per share. After $-0.70 actual earnings per share reported by Trillium Therapeutics Inc. for the previous quarter, Wall Street now forecasts -5.71% EPS growth.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $18.04 million. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

More notable recent Trillium Therapeutics Inc. (NASDAQ:TRIL) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Big Miss For Seattle Genetics (NASDAQ:SGEN); Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs – Benzinga” on February 08, 2019, also Seekingalpha.com with their article: “Trevena leads healthcare gainers; OPKO Health and Pain Therapeutics among losers – Seeking Alpha” published on February 05, 2019, Seekingalpha.com published: “Trillium’s TTI-621 shows encouraging action in early-stage studies – Seeking Alpha” on September 28, 2018. More interesting news about Trillium Therapeutics Inc. (NASDAQ:TRIL) were released by: Globenewswire.com and their article: “Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results – GlobeNewswire” published on November 14, 2018 as well as Seekingalpha.com‘s news article titled: “Trillium Therapeutics Updates On Lead Lymphoma Trials – Seeking Alpha” with publication date: October 04, 2018.

Piedmont Office Realty Trust, Inc. is a real estate investment trust. The company has market cap of $2.61 billion. The firm invests in real estate markets of the United States. It owns, manages, develops and operates high-quality, Class A office properties located in select sub markets of eight major Eastern U.S. office markets. It has a 20.74 P/E ratio. The firm was formerly known as Wells REIT, Inc.

The stock increased 0.49% or $0.1 during the last trading session, reaching $20.68. About 150,902 shares traded. Piedmont Office Realty Trust, Inc. (NYSE:PDM) has declined 6.09% since February 11, 2018 and is downtrending. It has underperformed by 6.09% the S&P500. Some Historical PDM News: 01/05/2018 – Piedmont Office Realty Trust Sees 1Q Core/FFO Shr $1.68-$1.74; 03/04/2018 – PIEDMONT OFFICE REALTY TRUST SAYS ON MARCH 29, CO’S UNIT ENTERED INTO A $250 MLN UNSECURED TERM LOAN FACILITY – SEC FILING; 21/04/2018 – DJ Piedmont Office Realty Trust Inc , Inst Holders, 1Q 2018 (PDM); 19/04/2018 – REG-Piedmont Announces First Quarter 2018 Leasing and Capital Markets Activity; 01/05/2018 – PIEDMONT OFFICE 1Q CORE FFO/SHR 45C, EST. 41C; 15/05/2018 – Brookfield Asset Management Buys 5.8% of Piedmont Office; 01/05/2018 – PIEDMONT OFFICE SEES FY CORE FFO/SHR $1.68 TO $1.74, EST. $1.69; 16/05/2018 – PIEDMONT OFFICE REALTY TRUST INC PDM.N : JP MORGAM RAISES TARGET PRICE TO $20 FROM $19; 01/05/2018 – PIEDMONT OFFICE 1Q REV. $129.9M; 03/04/2018 – PIEDMONT OFFICE REALTY TRUST – TERM OF $250 MLN UNSECURED TERM LOAN FACILITY IS SEVEN YEARS WITH A MATURITY DATE OF MARCH 31, 2025

More notable recent Piedmont Office Realty Trust, Inc. (NYSE:PDM) news were published by: Globenewswire.com which released: “Piedmont Office Realty Trust Announces Tax Treatment of 2018 Dividends – GlobeNewswire” on January 16, 2019, also Globenewswire.com with their article: “Piedmont Office Realty Trust to Report Fourth Quarter and Annual 2018 Financial Results – GlobeNewswire” published on January 11, 2019, Globenewswire.com published: “Piedmont Promotes C. Brent Smith to President and Chief Investment Officer – GlobeNewswire” on November 13, 2018. More interesting news about Piedmont Office Realty Trust, Inc. (NYSE:PDM) were released by: Globenewswire.com and their article: “Piedmont Closes on Sale of 800 North Brand in CA and Expands Boston Presence with Acquisition of 25 Burlington Mall Road in Burlington Submarket – GlobeNewswire” published on December 17, 2018 as well as Bizjournals.com‘s news article titled: “Exclusive: Tenant revealed for recent 300,000 SF Energy Corridor lease – Houston Business Journal” with publication date: October 12, 2018.

Investors sentiment decreased to 0.81 in Q3 2018. Its down 0.09, from 0.9 in 2018Q2. It fall, as 19 investors sold Piedmont Office Realty Trust, Inc. shares while 76 reduced holdings. 32 funds opened positions while 45 raised stakes. 105.74 million shares or 2.41% less from 108.35 million shares in 2018Q2 were reported. Numerixs Invest Techs invested 0.02% of its portfolio in Piedmont Office Realty Trust, Inc. (NYSE:PDM). Veritable Ltd Partnership stated it has 13,227 shares or 0.01% of all its holdings. Invesco Limited accumulated 246,859 shares. Shell Asset Mngmt Com has 44,218 shares. Amp Capital Invsts Limited stated it has 33,517 shares. Great West Life Assurance Can holds 84,679 shares. Voya Investment Ltd Liability Corp owns 41,786 shares. 72,754 were reported by Bowling Port Management Llc. Jpmorgan Chase reported 2.92 million shares. Qs Invsts Limited Company has invested 0.01% in Piedmont Office Realty Trust, Inc. (NYSE:PDM). Kestrel Investment Mgmt Corp stated it has 384,000 shares. Ameriprise Financial accumulated 198,326 shares or 0% of the stock. Meritage Portfolio Mgmt invested in 0.45% or 261,105 shares. Aperio Gp Ltd Co has invested 0% of its portfolio in Piedmont Office Realty Trust, Inc. (NYSE:PDM). Price T Rowe Associates Md reported 57,586 shares stake.

Piedmont Office Realty Trust, Inc. (NYSE:PDM) Institutional Positions Chart